EyePoint Pharmaceuticals (EYPT) Tops Q3 EPS by 14c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q3 EPS of ($0.49), $0.14 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $10.01 million versus the consensus estimate of $11.61 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
• QNB Corp. sells $254M in securities in portfolio repositioning